Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineEarly Treatment with Pegylated Interferon Lambda for COVID-19

The incidence of hospitalization or an emergency department visit (observation for more than 6 hours) was significantly lower among those who received a single dose of pegylated interferon lambda than among those who received a placebo.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form